Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 226.09% | Cantor Fitzgerald | → $3 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 552.17% | Canaccord Genuity | $5 → $6 | Maintains | Buy |
| 12/17/2021 | 769.57% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 12/03/2021 | 769.57% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/14/2023 | 226.09% | 坎託·菲茨傑拉德 | → 3 美元 | 重申 | 超重 → 超重 |
| 05/19/2023 | 552.17% | Canaccord Genu | 5 美元 → 6 美元 | 維護 | 購買 |
| 2021 年 12 月 17 日 | 769.57% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋開啓 | → 超重 |
| 2021 年 3 月 12 日 | 769.57% | Canaccord Genu | → 8 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Cardiol Therapeutics (CRDL)?
Cardiol Therapeutics（CRDL）的目標價格是多少？
The latest price target for Cardiol Therapeutics (NASDAQ: CRDL) was reported by Cantor Fitzgerald on August 14, 2023. The analyst firm set a price target for $3.00 expecting CRDL to rise to within 12 months (a possible 226.09% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月14日公佈了Cardiol Therapeutics（納斯達克股票代碼：CRDL）的最新目標股價。這家分析公司將目標股價定爲3.00美元，預計CRDL將在12個月內升至12個月內（可能上漲226.09％）。去年有2家分析公司公佈了評級。
What is the most recent analyst rating for Cardiol Therapeutics (CRDL)?
分析師對Cardiol Therapeutics（CRDL）的最新評級是多少？
The latest analyst rating for Cardiol Therapeutics (NASDAQ: CRDL) was provided by Cantor Fitzgerald, and Cardiol Therapeutics reiterated their overweight rating.
Cardiol Therapeutics（納斯達克股票代碼：CRDL）的最新分析師評級由坎託·菲茨傑拉德提供，Cardiol Therapeutics重申了他們的增持評級。
When is the next analyst rating going to be posted or updated for Cardiol Therapeutics (CRDL)?
Cardiol Therapeutics（CRDL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiol Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiol Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cardiol Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Cardiol Therapeutics的最後一次評級是在2023年8月14日提交的，因此你應該預計下一個評級將在2024年8月14日左右公佈。
Is the Analyst Rating Cardiol Therapeutics (CRDL) correct?
分析師對 Cardiol Therapeutics (CRDL) 的評級正確嗎？
While ratings are subjective and will change, the latest Cardiol Therapeutics (CRDL) rating was a reiterated with a price target of $0.00 to $3.00. The current price Cardiol Therapeutics (CRDL) is trading at is $0.92, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Cardiol Therapeutics（CRDL）評級得到了重申，目標股價爲0.00美元至3.00美元。Cardiol Therapeutics（CRDL）目前的交易價格爲0.92美元，在分析師的預測區間內。